NKTR vs QCOM · rev $21.0M vs P/E 16, rev $44.28B
Nektar Therapeutics (NKTR) versus Qualcomm Incorporated (QCOM) — a side-by-side from cached financials, not a winner call.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Qualcomm Incorporated (QCOM) is a semiconductors company listed on US. It is led by Cristiano Amon.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
Latest reported QCOM revenue for 2025-09-28 was $44.28B. Net income was $5.54B. QCOM currently screens at market cap $175.02B and trailing P/E 16.3.
NKTR currently screens at market cap $307.2M. QCOM currently screens at market cap $175.02B and trailing P/E 16.3.
Not investment advice. Open the NKTR and QCOM stock pages for the full models.
Not investment advice.